Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.
In this editorial, Matthew Stoll explores the role of the microbiota in the pathogenesis of juvenile idiopathic arthritis, as well as current research into therapeutic alterations of the microbiome.
The tumor necrosis factor inhibitor certolizumab pegol could be an option for patients with active nonradiographic axial spondyloarthritis and objective signs of inflammation, indicate phase III trial results.
Findings from a proof-of-concept study suggest that deep learning models based on electronic health records may be a feasible approach for forecasting disease outcomes in people with rheumatoid arthritis.
Progressive skin fibrosis is significantly associated with worsening lung function and an increased risk for death among patients with diffuse cutaneous systemic sclerosis, an analysis of EUSTAR data shows.
Rheumatoid arthritis patients with high disease activity are more likely to have cognitive impairment than those with less active disease, researchers report.
Findings from a systematic review and meta-analysis suggest that nearly half of patients with rheumatoid arthritis in remission experience disease relapse after elective discontinuation of tumor necrosis factor inhibitors.
Results of a systematic review suggest that treatment with acetaminophen provides only minimal benefit compared with placebo for patients with osteoarthritis.
Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.
medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.
The US FDA warns that treatment with the Janus kinase inhibitor tofacitinib at a dose of 10 mg twice daily is associated with an increased risk for pulmonary embolism and death in patients with rheumatoid arthritis.
